Co-Diagnostics, ReadyGo collaborate on blood-based PCR testing, starting with Ebola

Co-Diagnostics, Inc.

Collaboration to test ReadyGo's GoCollect sample-prep with Co-Dx PCR platform for blood-based molecular testing at point of need.
Initial focus on decentralized Ebola detection; WHO cites 6,757 confirmed cases, 3,267 deaths in DRC outbreak as of Sept 7, 2026.
Feasibility work underway; no compatibility established yet; Co-Dx PCR platform not FDA cleared or available for sale.
Success could expand platform to bloodborne pathogens including HIV and hepatitis B/C, representing larger markets than current swab menu.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.